The COVID-19 lateral flow antigen test (colloidal gold) from Beijing Wantai Biological Pharmacy is a lateral flow assay for the qualitative detection of SARS-CoV-2 nucleocapsid antigen from nasopharyngeal (NP) and oropharyngeal (OP) swab specimens in just 20 minutes. These tests are intended for the screening of patients suspected of SARS-CoV-2 infection and to aid in the diagnosis of COVID-19. These kits are in stock now and available for immediate delivery.
The Wantai SARS-CoV-2 Ag Rapid Test (Colloidal Gold) (CE-IVD) is intended for professional use only. This kit is for use by a healthcare professional or an individual trained in immunoassay techniques who can carry out the test as detailed in the instructions for use and interpret the test results accordingly. Tests will only be supplied to those who agree to arrange for an individual(s) who falls into the healthcare professional/trained professional category to be responsible for carrying out the tests.
Benefits of using the COVID-19 lateral flow antigen test
• COVID-19 lateral flow test: suitable for rapid, on-site testing
• Fast: result within only 20 minutes
• Sensitive: 93.44% (57/61)
• Specific: 100% (87/87)
• Easy-to-use: no specialist equipment required
• CE marked
• In stock and available for immediate delivery
This kit employs lateral flow immunochromatography combined with a double antibody sandwich method in a cassette format. Antibodies to SARS-COV-2 are coated at the test line on the nitrocellulose membrane, and colloidal gold conjugated antibodies to SARS-COV-2 are dry-immobilized at the colloidal gold pad.
If SARS-COV-2 nucleocapsid antigen is present in the specimen, particles of "coated antibody-antigen-colloidal gold conjugated antibody" will be formed, and these particles aggregate at the Test Zone (T) to form a red line. If there is no SARS-CoV-2 nucleocapsid antigen in the specimen, no red line will be formed at the Test Zone (T). Secondary antibodies coated at the control line on the nitrocellulose membrane capture the colloidal gold conjugated antibody to form a red line at the Control Zone (C), indicating the validity of the test.
A total of 148 samples, including oropharyngeal swabs and nasopharyngeal swabs, were collected from 61 confirmed COVID-19 cases within 7 days of onset and 87 excluded COVID-19 cases were evaluated. The test results were compared with the test results by RT-PCR. The results show that the positive percent agreement of the test was 93.44% (57/61) and the negative percent agreement was 100.00% (87/87). The limit of detection (LoD) of 20 pg/mL for this test was established using limiting dilutions of the Nucleocapsid Protein China National Reference Material of Corona Virus Disease 2019 (code: GBW(E)091097). The limit of detection (LoD) was 230 TCID50/ml.
Note: product availability depends on country - see product detail page.
|Details||Cat number & supplier||Size||Price|
|SARS-CoV-2 Ag Rapid Test (Colloidal Gold) (CE-IVD) WJ-2950 · Beijing Wantai Biological Pharmacy||
WJ-2950Beijing Wantai Biological Pharmacy